These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 30016656)

  • 1. Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation.
    Afrough A; Saliba RM; Hamdi A; Honhar M; Varma A; Cornelison AM; Rondon G; Parmar S; Shah ND; Bashir Q; Hosing C; Popat U; Weber DM; Thomas S; Orlowski RZ; Champlin RE; Qazilbash MH
    Biol Blood Marrow Transplant; 2018 Nov; 24(11):2197-2203. PubMed ID: 30016656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
    Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
    Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation.
    Afrough A; Saliba RM; Hamdi A; El Fakih R; Varma A; Dinh YT; Rondon G; Cornelison AM; Shah ND; Bashir Q; Shah JJ; Hosing C; Popat U; Orlowski RZ; Champlin RE; Parmar S; Qazilbash MH
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1413-7. PubMed ID: 25842049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.
    Gupta VK; Brauneis D; Shelton AC; Quillen K; Sarosiek S; Sloan JM; Sanchorawala V
    Biol Blood Marrow Transplant; 2019 May; 25(5):e169-e173. PubMed ID: 30639823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.
    Sanchorawala V; Brauneis D; Shelton AC; Lo S; Sun F; Sloan JM; Quillen K; Seldin DC
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1445-51. PubMed ID: 25858810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis.
    Oke O; Sethi T; Goodman S; Phillips S; Decker I; Rubinstein S; Concepcion B; Horst S; Jagasia M; Kassim A; Harrell SL; Langone A; Lenihan D; Rawling KT; Slosky D; Cornell RF
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1473-1477. PubMed ID: 28546074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant.
    Gaballa S; Saliba RM; Srour S; Lu G; Brammer JE; Shah N; Bashir Q; Patel K; Bock F; Parmar S; Hosing C; Popat U; Delgado R; Rondon G; Shah JJ; Manasanch EE; Orlowski RZ; Champlin R; Qazilbash MH
    Am J Hematol; 2016 Oct; 91(10):E442-7. PubMed ID: 27420405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
    Nguyen VP; Landau H; Quillen K; Brauneis D; Shelton AC; Mendelson L; Rahman H; Sloan JM; Sarosiek S; Sanchorawala V
    Biol Blood Marrow Transplant; 2018 Sep; 24(9):1823-1827. PubMed ID: 29933072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.
    Veltri LW; Milton DR; Delgado R; Shah N; Patel K; Nieto Y; Kebriaei P; Popat UR; Parmar S; Oran B; Ciurea S; Hosing C; Lee HC; Manasanch E; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH; Bashir Q
    Cancer; 2017 Sep; 123(18):3568-3575. PubMed ID: 28513828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A real-life cohort study of immunoglobulin light-chain (AL) amyloidosis patients ineligible for autologous stem cell transplantation due to severe cardiac involvement or advanced disease.
    Brunger AF; Nienhuis HLA; Bijzet J; Roeloffzen WWH; Vellenga E; Hazenberg BPC
    Amyloid; 2020 Jun; 27(2):119-127. PubMed ID: 32052655
    [No Abstract]   [Full Text] [Related]  

  • 11. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
    Scott EC; Heitner SB; Dibb W; Meyers G; Smith SD; Abar F; Kovacsovics T; Perez-Avraham G; Stentz A; Frires R; Dibb J; Maziarz RT
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell Transplantation.
    Dittus C; Uwumugambi N; Sun F; Sloan JM; Sanchorawala V
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1729-1732. PubMed ID: 27296954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The choice of multiple myeloma induction therapy affects the frequency and severity of oral mucositis after melphalan-based autologous stem cell transplantation.
    Fleming S; Harrison SJ; Blombery P; Joyce T; Stokes K; Seymour JF; Prince HM; Ritchie D
    Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):291-6. PubMed ID: 24629850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved.
    Al Saleh AS; Sidiqi MH; Muchtar E; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Warsame RM; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1520-1525. PubMed ID: 31054986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Outcome of Autologous Hematopoietic Cell Transplantation in Adult Patients with Acute Myeloid Leukemia: Who May Benefit from Autologous Hematopoietic Cell Transplantation?
    Yoon JH; Kim HJ; Park SS; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):588-597. PubMed ID: 28089879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis.
    Badar T; Khan MA; Szabo A; Drobyski W; Chhabra S; Dhakal B; Fenske TS; Hamadani M; Hari P; Jerkins JH; Shah NN; Shaw BE; D'Souza A
    Amyloid; 2019 Dec; 26(4):210-215. PubMed ID: 31347424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation.
    Jacobs RW; Saliba RM; Sasaki K; Farhan S; Armas A; Shah ND; Bashir Q; Qureshi S; Rondon G; Hosing C; Popat U; Parmar S; Shah JJ; Wang M; Weber DM; Thomas SK; Orlowski RZ; Champlin RE; Qazilbash MH
    Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):36-42. PubMed ID: 26702475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma Over Three Decades.
    Pasvolsky O; Marcoux C; Dai J; Milton DR; Tanner MR; Syed N; Bashir Q; Srour S; Saini N; Lin P; Ramdial J; Nieto Y; Tang G; Aljawai Y; Lee HC; Gaballa MR; Patel KK; Kebriaei P; Thomas SK; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
    Transplant Cell Ther; 2024 Aug; 30(8):772.e1-772.e11. PubMed ID: 38852784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation.
    Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kapoor P; Kourelis TV; Hogan WJ; Wolf RC; Kumar SK; Gertz MA
    Bone Marrow Transplant; 2019 Jul; 54(7):1077-1081. PubMed ID: 30390060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation.
    Pun SC; Landau HJ; Riedel ER; Jordan J; Yu AF; Hassoun H; Chen CL; Steingart RM; Liu JE
    J Am Soc Echocardiogr; 2018 Jan; 31(1):64-70. PubMed ID: 29111123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.